Clinical Trial Detail

NCT ID NCT03432741
Title Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Mayo Clinic
Indications

cutaneous T cell lymphoma

non-Hodgkin lymphoma

breast adenocarcinoma

Hodgkin's lymphoma

Therapies

Carfilzomib

Daratumumab

Obinutuzumab

Gemcitabine

Trastuzumab

romidepsin

Nivolumab

Rituximab

Belinostat

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.